At the news
? NEUTRALIMPACT 3/10 DEFA14A filed Apr 24, 2026 at 16:30 ET
Apogee Therapeutics is holding its annual shareholder meeting to vote on the re-election of three Class III directors, ratification of its auditor, and advisory approval of executive compensation. This routine proxy filing follows recent board resignations, suggesting potential governance changes, but the filing itself contains no new material information.
- Annual shareholder meeting to vote on re-election of three Class III directors: Mark C. McKenna, Jennifer Fox, and William (BJ) Jones, Jr.
- Vote to ratify Ernst & Young LLP as independent auditor.
- Advisory vote to approve compensation of named executive officers.
- Recent context: Two board members resigned effective May 11, 2026, just prior to this proxy filing.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access